Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,808

Document Document Title
WO/2018/197653A9
The present invention relates to crystalline polymorph forms of (5)-2-((2-((5)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[ƒ]imidazo[ 1,2-J] [ 1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula ...  
WO/2019/175253A1
The present invention generally relates to novel pharmaceutical formulations containing 2- [3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphen yl)-6-[(7S,9aS)-7- (hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl] -3-py...  
WO/2019/178091A1
Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1 : pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1 )) interact...  
WO/2019/173633A1
Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein X is selected from the group consisting of -O-, -S-, -NR14-O-, -O-NR14-, -NR14-NR15- and -S-S-; R1― R15, m, n, o, p, q and r are as defined herein, are pr...  
WO/2019/170086A1
Provided are an acyl-substituted oxazino-quinazoline compound, a preparation method therefor, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable...  
WO/2019/173181A1
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stere...  
WO/2019/173640A1
In certain embodiments, this disclosure relates to methods of treating or preventing type 2 diabetes, pre-diabetes and conditions characterized by an increase in the levels of AIC, glucose, insulin, homeostasis model of assessment of ins...  
WO/2019/169539A1
Provided herein are oxa- and aza-tricyclic 4-pyridone-3-carboxylic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for inhibiting HBsAg secretion and HBV DNA production, and fo...  
WO/2019/169504A1
We evaluated the antibacterial activity of synthetic short proline-rich lipopeptides (SPRLPs) against clinically-relevant Gram-positive and Gram-negative pathogens. The short peptide sequence of SPRLPs were inspired by the repeating PXP ...  
WO/2019/170088A1
Provided are an oxazino-quinazoline and oxazino-quinazoline type compound, a preparation method therefor, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceuticall...  
WO/2019/166950A1
The present disclosure refers to 10-(di(phenyl)methyl)-4- hydroxy-8,9,9a,10-tetrahydro-7H-pyrrolo[1';2':4,5]pyrazino[1 ,2- b]pyridazine-3,5-dione derivatives and related compounds of Formula (A) as inhibitors of the orthomyxovirus replic...  
WO/2019/165073A1
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further ...  
WO/2019/158634A1
The present invention relates to deuterated derivatives of 9-(2,5-difluorophenethyl)-4- ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one having pharmacological activity, to processes of preparation of such compounds, to pharmaceutic...  
WO/2019/161345A1
Compounds are described with the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and n are defined as anywhere herein, which are useful for the treatment of cancer and other dysproliferative diseases.  
WO/2019/159199A1
The present invention discloses continues flow process for the preparation of polycyclic carbamoyl pyridone derivatives and intermediates thereof. In particular, the present invention discloses a process for the preparation of intermedia...  
WO/2019/158731A1
The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation,...  
WO/2019/156987A1
Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: (I) wherein the letters and sym...  
WO/2019/154634A1
The present invention relates to a crystalline form of bictegravir sodium and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline form of bictegravir sodium, pr...  
WO/2018/119362A8
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2019/157374A1
The present invention relates to a novel rapamycin analogue of Formula (I), mixtures, methods for its production, and its use in preventing and/or treating a neurodegenerative condition.  
WO/2019/149657A1
The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modula...  
WO/2019/149131A1
The present disclosure relates to a compound represented by general formula (1), the compound being a small molecular kinase inhibitor having a macrocyclic molecular structure. The present disclosure also relates to a pharmaceutical comp...  
WO/2019/149659A1
The present invention relates to compounds of general formula (I) wherein the variables X, R1, n, p and q are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) ...  
WO/2019/149658A1
The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate...  
WO/2019/151274A1
The present invention provides a compound which has a PDHK-inhibiting activity and is useful for the treatment or prevention of diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglyc...  
WO/2019/149158A1
The present invention relates to nitrogenous tricyclic compounds and uses thereof in medicine, in particular, the present invention discloses a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a ge...  
WO/2019/147753A1
The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful. The present disclosure further includes compositions and methods for treating or preventing a bacteri...  
WO/2019/147742A1
A pro-fragrance delivery system based on a vitamin scaffold and a fragrant alcohol. The vitamin scaffold may be a vitamer of vitamin B6 or derivatives thereof. The pro-fragrance releases the fragrant alcohol by action of water at neutral...  
WO/2019/141096A1
Provided is a substituted urea compound, and a preparation method and use thereof. More particularly, the invention relates to a substituted urea compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorphic substance, a ...  
WO/2019/143677A1
Compounds, methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene...  
WO/2019/141179A1
The present invention relates to the field of medical chemistry, and relates to a novel pyridone derivative represented by formula (I) or a stereoisomer thereof, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and an ...  
WO/2019/143718A1
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions,...  
WO/2019/129025A1
The present invention discloses a tetrahydropyrrole compound, a preparation method therefor, a pharmaceutical composition containing the same, and a use thereof. The tetrahydropyrrole compound of the present invention is represented by g...  
WO/2019/131798A1
Provided is a cell growth inhibitor containing, as an active ingredient, a compound represented by general formula (1) below, or a pharmacologically acceptable salt thereof. [In general formula (1), J1 and J2 represent CH or N, but both ...  
WO/2019/128963A1
Disclosed is a substituted nitroimidazole derivative, in particular, disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a pharmaceutical composition comprising the abov...  
WO/2019/121843A1
The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2019/119141A1
The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and...  
WO/2019/126731A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described ...  
WO/2019/126622A1
Provided herein are isoxazole compounds, pharmaceutical compositions thereof, methods of preparing such compounds and compositions, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2019/119207A1
Provided are compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.  
WO/2019/120213A1
The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as...  
WO/2019/120267A1
Disclosed is an imidazo[1,2-b]pyridazine macrocyclic kinase inhibitor. The compound or a stereoisomer, or a crystal form, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a metabolite thereof is as shown in formula (...  
WO/2019/126730A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are d...  
WO/2019/111218A1
The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatmen...  
WO/2019/110751A1
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them an...  
WO/2019/109188A1
The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.  
WO/2019/110413A1
The present invention relates to the improved synthesis of noroxymorphone of formula (III). Particularly, the invention shows a way how to reduce the impurity level in the product avoiding lengthy purification steps.  
WO/2019/110006A1
Disclosed are a compound represented by the general formula (I), or a stereisomer, a tautomer, a derivative, a prodrug or a pharmaceutically acceptable salt thereof, and a method for preparing the compound and the use of the compound in ...  
WO/2019/110613A1
The present invention relates to a novel process for the synthesis of herbicidal pyrazolidinedione compounds. In particular, a process for the preparation of a compound of formula (I), wherein R1, R2 and R3 are as defined herein. The pre...  
WO/2019/108591A1
The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof (1) wherein each of R1, R2, R3, R4, L1, and L2, are as defined herein. The present invention also contempl...  

Matches 1 - 50 out of 13,808